Scientists studying a bacterium that causes scarlet fever, severe sore throat and a form of heart disease are developing a vaccine that could prevent hundred of thousands of infections a year.
Merck & Co.’s investigational 15-valent pneumococcal conjugate vaccine was “noninferior” to a currently available 13-valent pneumococcal conjugate vaccine in healthy babies 6 to 12 weeks of age.
Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.
The U.S. Food and Drug Administration approved ADMA Biologics’ Asceniv to treat primary humoral immunodeficiency disease (PIDD or PI) in adults and adolescents.
A bacteriophage is a virus that infects bacteria. They are not typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.
Motif Bio plc announced today that the clinical-stage biopharmaceutical company received a complete response letter from the U.S. Food and Drug Administration regarding the new drug application for iclaprim for the treatment of acute bacterial skin and skin structure infections.
Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.
Researchers at New York University School of Medicine and Janssen Research & Development, a Johnson & Johnson company, developed a new class of engineered proteins that may help fight the bacteria that cause Staph infections.
A federal judge in Maryland said The Johns Hopkins University, Bristol-Myers Squibb Co. and the Rockefeller Foundation must face a $1 billion lawsuit over their roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with syphilis.
RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!
